The Cigna Group SEC filings document financial results, governance actions and material events for a global health company operating through Cigna Healthcare, Evernorth Health Services and related subsidiaries. Form 8-K reports cover results of operations and financial condition, Regulation FD outlook disclosures, board and committee changes, leadership succession matters and shareholder meeting results.
Proxy materials describe director elections, executive compensation, shareholder voting items, board composition and governance practices. The filing record also includes exhibits for earnings releases and Inline XBRL cover data, tying formal disclosures to the company’s pharmacy benefit services, specialty and care services, health benefits operations, compliance oversight and public-company capital structure.
The Cigna Group prospectus supplement describes an offering of multiple series of senior unsecured notes (the "Notes") with various maturities and interest rates, to be issued in book-entry form through DTC and delivered on or about September 2025. Interest will accrue from 2025 and is payable semiannually beginning in 2026. The Notes are senior, unsecured and unsubordinated, rank equally with other senior unsecured indebtedness, will be structurally subordinated to subsidiary liabilities and effectively junior to secured debt to the extent of collateral. The issuer may optionally redeem the Notes under specified terms and must offer to repurchase Notes at 101% upon a change of control triggering event. The prospectus discusses tax treatment, DTC mechanics, events of default, amendment mechanics, defeasance options and ERISA considerations.
The Cigna Group registers securities for public offering and describes terms applicable to debt securities, trustee rights, defaults and amendment mechanics. The prospectus outlines the specific items that will be set for each debt series, including interest rates, payment dates, redemption and conversion features, denominations, currencies, paying agents and any sinking-fund or prepayment provisions. It explains Events of Default (missed payments, covenant breaches, insolvency) and holders' remedies, including acceleration subject to majority rescission rights.
The document clarifies that debt may be fungibly reissued, that most amendments require a majority of affected holders but certain changes need unanimous consent, and that debt securities generally do not include change-of-control repurchase rights unless stated in a prospectus supplement. It also covers defeasance options, transfer agent (Computershare), NYSE listing (CI), ERISA considerations for plan investors, indemnification of directors and officers and reliance on PwC for audited financials.
The Cigna Group filed an update stating that company officials expect to reaffirm their outlook for full year 2025, targeting consolidated adjusted income from operations of at least $29.60 per share. This guidance will be reiterated in upcoming meetings with investors and analysts, and is consistent with the outlook previously discussed in a July 31, 2025 press release and conference call.
The company explains that adjusted income from operations is a non-GAAP profitability measure that starts from shareholders’ net income and excludes net investment gains and losses, amortization of acquired intangible assets, certain joint venture investment results and special items that management views as not representative of underlying operations. Cigna notes that it cannot provide a forward-looking reconciliation to shareholders’ net income because items like future investment results and special items are inherently uncertain and could vary materially.
Nicole S. Jones, EVP, Chief Administrative Officer and General Counsel of The Cigna Group (CI), reported multiple transactions under a Rule 10b5-1 plan. On 08/15/2025 and 08/18/2025 she executed option exercises and open-market trades: option-related acquisitions of 13,155 and 11,598 shares at exercise prices of $197.35 and $183.4405, additional option exercises of 1,348 and 1,329 shares, and a reported sale of 28,526 shares at $300 on 08/15/2025. Following these transactions her reported beneficial ownership positions changed across reported lines (examples shown: 42,576; 54,174; 25,648; 26,996; 28,325). She also holds 1,419.6518 shares indirectly via the company 401(k) plan. The Form 4 states the trades were effected pursuant to a 10b5-1 plan adopted May 8, 2025, and lists Tyler Gratton as attorney-in-fact who signed the filing on 08/19/2025.
Form 144 filing for Cigna (CI) reports a proposed sale of 28,526 common shares through Fidelity Brokerage Services on the NYSE, with an aggregate market value of $8,557,800 and approximately 266,928,075 shares outstanding. The shares to be sold were acquired via restricted stock vesting (1,137 shares on 03/01/2024) and option exercises or option-related transactions (2,636 shares on 08/13/2024; 13,155 shares and 11,598 shares with dates shown as 08/15/2025 tied to options granted in 2018 and 2019). No securities were reported sold in the past three months. The filer attests they are not aware of any material nonpublic information.
Cigna Group (CI) submitted a Form 144 proposing the sale of 35,711 shares of its common stock, with an aggregate market value of $9,822,667.66, to be executed on 08/12/2025 through Fidelity Brokerage Services LLC on the NYSE. The filing lists total shares outstanding of 266,928,075 and shows the securities to be sold were acquired through option exercises and restricted stock vesting between 02/26/2021 and 08/12/2025, with some purchases paid in cash and others issued as compensation.
The filer reports no securities sold by the same person in the past three months and includes the standard attestation that the seller has no undisclosed material information; the notice is marked LIVE.